Trust Company’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $704K | Buy |
5,572
+2,065
| +59% | +$272K | 0.06% | 85 |
|
|
2026
Q1 | $489K | Sell |
3,507
-259
| -7% | -$36.3K | 0.05% | 119 |
|
|
2025
Q4 | $462K | Buy |
3,766
+1,530
| +68% | +$186K | 0.04% | 120 |
|
|
2025
Q3 | $248K | Sell |
2,236
-1,996
| -47% | -$227K | 0.03% | 127 |
|
|
2025
Q2 | $469K | Sell |
4,232
-1,279
| -23% | -$136K | 0.05% | 86 |
|
|
2025
Q1 | $618K | Sell |
5,511
-1,972
| -26% | -$203K | 0.07% | 76 |
|
|
2024
Q4 | $691K | Buy |
7,483
+1,229
| +20% | +$111K | 0.08% | 71 |
|
|
2024
Q3 | $524K | Sell |
6,254
-806
| -11% | -$61.5K | 0.06% | 84 |
|
|
2024
Q2 | $484K | Buy |
7,060
+808
| +13% | +$53.9K | 0.06% | 87 |
|
|
2024
Q1 | $458K | Sell |
6,252
-3,802
| -38% | -$292K | 0.06% | 86 |
|
|
2023
Q4 | $814K | Buy |
10,054
+439
| +5% | +$34.2K | 0.1% | 62 |
|
|
2023
Q3 | $721K | Buy |
9,615
+5,687
| +145% | +$437K | 0.12% | 64 |
|
|
2023
Q2 | $303K | Buy |
3,928
+3,323
| +549% | +$265K | 0.05% | 121 |
|
|
2023
Q1 | $50.2K | Sell |
605
-1,653
| -73% | -$137K | 0.01% | 186 |
|
|
2022
Q4 | $194K | Sell |
2,258
-12,558
| -85% | -$994K | 0.03% | 136 |
|
|
2022
Q3 | $914K | Buy |
14,816
+6,055
| +69% | +$382K | 0.2% | 51 |
|
|
2022
Q2 | $542K | Sell |
8,761
-14,139
| -62% | -$875K | 0.12% | 79 |
|
|
2022
Q1 | $1.36M | Buy |
22,900
+3,348
| +17% | +$214K | 0.27% | 47 |
|
|
2021
Q4 | $1.42M | Buy |
19,552
+514
| +3% | +$35.4K | 0.33% | 37 |
|
|
2021
Q3 | $1.33M | Sell |
19,038
-968
| -5% | -$68K | 0.34% | 36 |
|
|
2021
Q2 | $1.38M | Sell |
20,006
-39
| -0.2% | -$2.6K | 0.97% | 26 |
|
|
2021
Q1 | $1.3M | Buy |
20,045
+5,962
| +42% | +$384K | 0.93% | 29 |
|
|
2020
Q4 | $820K | Buy |
14,083
+2,736
| +24% | +$165K | 0.65% | 47 |
|
|
2020
Q3 | $717K | Buy |
11,347
+455
| +4% | +$31.6K | 0.6% | 54 |
|
|
2020
Q2 | $838K | Buy |
10,892
+1,321
| +14% | +$101K | 0.8% | 36 |
|
|
2020
Q1 | $716K | Sell |
9,571
-219
| -2% | -$15.1K | 0.79% | 36 |
|
|
2019
Q4 | $636K | Buy |
9,790
+642
| +7% | +$41.8K | 0.56% | 47 |
|
|
2019
Q3 | $580K | Sell |
9,148
-2,663
| -23% | -$174K | 0.55% | 49 |
|
|
2019
Q2 | $798K | Sell |
11,811
-27,016
| -70% | -$1.78M | 0.73% | 44 |
|
|
2019
Q1 | $2.52M | Buy |
38,827
+38,747
| +48,434% | +$2.58M | 1.47% | 26 |
|
|
2018
Q4 | $5K | Hold |
80
| – | – | ﹤0.01% | 287 |
|
|
2018
Q3 | $6K | Sell |
80
-157
| -66% | -$11.9K | ﹤0.01% | 294 |
|
|
2018
Q2 | $17K | Sell |
237
-7,458
| -97% | -$527K | 0.01% | 245 |
|
|
2018
Q1 | $580K | Sell |
7,695
-75,466
| -91% | -$6M | 0.21% | 55 |
|
|
2017
Q4 | $5.96M | Buy |
83,161
+6,903
| +9% | +$524K | 2.46% | 16 |
|
|
2017
Q3 | $6.18M | Sell |
76,258
-4,476
| -6% | -$342K | 3.4% | 16 |
|
|
2017
Q2 | $5.71M | Buy |
80,734
+29,967
| +59% | +$1.99M | 2.64% | 16 |
|
|
2017
Q1 | $3.45M | Buy |
50,767
+4,088
| +9% | +$287K | 1.57% | 27 |
|
|
2016
Q4 | $3.34M | Sell |
46,679
-3,517
| -7% | -$261K | 1.7% | 26 |
|
|
2016
Q3 | $3.97M | Buy |
50,196
+8,251
| +20% | +$670K | 1.74% | 20 |
|
|
2016
Q2 | $3.5M | Sell |
41,945
-537
| -1% | -$47.7K | 1.34% | 27 |
|
|
2016
Q1 | $3.9M | Buy |
42,482
+4,749
| +13% | +$428K | 1.79% | 14 |
|
|
2015
Q4 | $3.82M | Buy |
37,733
+3,202
| +9% | +$333K | 1.77% | 13 |
|
|
2015
Q3 | $3.39M | Buy |
34,531
+9,353
| +37% | +$1.04M | 1.92% | 9 |
|
|
2015
Q2 | $2.95M | Buy |
25,178
+1,653
| +7% | +$181K | 1.84% | 6 |
|
|
2015
Q1 | $2.31M | Buy |
+23,525
| New | +$2.39M | 1.46% | 16 |
|
Other funds holding GILD
Trust Company's GILD Position: Q2 2026 in Review
Trust Company increased its Gilead Sciences (GILD) stake by 59% in Q2 2026, buying an estimated $272K and bringing the position to 5,572 shares worth $704K. The position accounts for 0.06% of the portfolio, ranked #85.
Trust Company first reported a position in GILD in Q1 2015 and has held it in 46 quarters since. The position peaked at $6.18M in Q3 2017. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Trust Company held 5,572 shares of Gilead Sciences worth $704K as of Q2 2026.
- Trust Company bought 2,065 Gilead Sciences shares in Q2 2026, an estimated $272K.
- Gilead Sciences made up 0.06% of Trust Company's portfolio in Q2 2026, its #85 holding.
- Trust Company first reported a position in Gilead Sciences in Q1 2015 and has held it in 46 quarters since.
- Trust Company's Gilead Sciences position peaked at $6.18M in Q3 2017.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.